SAHPRA – The South African Health Products Regulatory Authority (SAHPRA) has reassured the public that all cancer medication used in South Africa complies with national and international health and safety standards. This announcement comes in response to a recent Lancet Global Health study that raised serious concerns about the quality of anti-cancer drugs being distributed in parts of sub-Saharan Africa.
The investigational study, which has garnered international attention, revealed that substandard cancer medication is being marketed and sold in several African countries. The findings have sparked concern among healthcare professionals, patients, and regulatory bodies about the possible public health risks posed by low-quality or counterfeit cancer drugs in the region.
In light of the alarming report, SAHPRA initiated a thorough internal review to ensure that cancer patients in South Africa are not being exposed to any compromised medication. The agency confirmed that none of the cancer treatments registered or sold in the country were found to be affected by the concerns raised in the study.
SAHPRA Takes Proactive Steps to Assess Cancer Medication Quality
Speaking on behalf of the regulatory body, SAHPRA spokesperson Yuven Gounden emphasized that the organization acted swiftly to investigate any possible links between the substandard drugs highlighted in the study and the products available within South Africa.
“Following the release of the Lancet Global Health report, SAHPRA began internal processes to verify whether any of the South African-registered cancer medications were implicated or potentially affected,” said Gounden.
He added, “SAHPRA is satisfied that the marketed and registered cancer medicines in South Africa meet the appropriate specifications. Therefore, no substandard cancer medicines were detected.”
This statement has come as a major relief for patients undergoing cancer treatment in the country, as well as for medical professionals and oncology institutions who rely on the integrity of the pharmaceutical supply chain.
The original study conducted by Lancet Global Health focused on a cross-sectional analysis of anti-cancer medications available in multiple countries across sub-Saharan Africa. The researchers found that some of these products contained incorrect dosages, impurities, or lacked essential active ingredients altogether—posing significant risks to patient health and survival.
The distribution of low-quality or counterfeit cancer medication undermines the fight against cancer, particularly in regions where access to treatment is already limited. Poor-quality drugs can lead to treatment failure, drug resistance, prolonged suffering, and, in the worst cases, death.
In response to the study’s findings, health authorities across the continent are now reassessing their drug procurement and regulatory procedures. South Africa, with its comparatively strong regulatory infrastructure, has taken a leading role in ensuring that only approved and tested medications are made available to its citizens.
The assurance from SAHPRA is a reflection of the agency’s ongoing commitment to safeguarding public health. Over the years, SAHPRA has built a reputation for rigorous testing, strict regulatory oversight, and continuous monitoring of pharmaceuticals in the South African market.
According to Gounden, the authority will continue to review imported products and remain vigilant in monitoring global pharmaceutical trends—especially where there is a potential risk to public health.
“SAHPRA remains committed to protecting the public by ensuring that all medicines, including cancer medication, meet the highest standards of safety, quality, and efficacy,” he said.
While SAHPRA’s findings are reassuring, patients and healthcare providers are encouraged to remain cautious and informed. Experts advise cancer patients to always obtain medication from registered pharmacies and licensed healthcare providers. Patients should also report any adverse reactions or suspicious products to SAHPRA for investigation.
Healthcare professionals are advised to stay up to date with official SAHPRA advisories and to report any concerns related to the sourcing, quality, or performance of anti-cancer treatments.
The recent concerns raised by the Lancet Global Health report about substandard cancer medication in parts of Africa have highlighted the vital role that regulatory authorities play in protecting public health. Thanks to SAHPRA’s proactive measures and strict oversight, South Africans can be confident that the cancer treatments available in the country meet globally accepted standards.
As cancer cases continue to rise across the continent, ensuring the safety and quality of cancer medication remains an essential part of delivering effective healthcare. Transport Minister Creecy and the Department of Health have both expressed support for strengthening regulatory frameworks and supply chain transparency moving forward.
Source- EWN
